about
Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatmentRegulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cellsInvolvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functionsA new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products.The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.The Ras family of GTPases in cancer cell invasion.A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomasLocalization of rap1 and rap2 proteins in the gelatinase-containing granules of human neutrophils.Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?Choline kinase inhibition in rheumatoid arthritis.Rho GTPases: potential candidates for anticancer therapy.Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites.Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation.Rho GTPase expression in tumourigenesis: evidence for a significant link.A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cellsPhospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma.Human urine proteomics: building a list of human urine cancer biomarkers.Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium.Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors.Preclinical characterization of RSM-932A, a novel anticancer drug targeting the human choline kinase alpha, an enzyme involved in increased lipid metabolism of cancer cells.Acid ceramidase as a chemotherapeutic target to overcome resistance to the antitumoral effect of choline kinase α inhibition.Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viabilitySTAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoAROCK and nuclear factor-kappaB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences.Choline kinase alpha depletion selectively kills tumoral cells.Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy.Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.Symmetrical bis-quinolinium compounds: new human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line.Influence of the linker in bispyridium compounds on the inhibition of human choline kinase.Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action.New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties.Choline kinase inhibitory effect and antiproliferative activity of new 1,1',1"-(benzene-1,3,5-triylmethylene)tris[4-[(disubstituted)amino]pyridinium] tribromides.Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds.Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity.Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling.Activation of phospholipase D by ras proteins is independent of protein kinase C.Antiplasmodial activity and mechanism of action of RSM-932A, a promising synergistic inhibitor of Plasmodium falciparum choline kinase.Screening for new compounds with antiherpes activity.Signaling from G protein-coupled receptors to the c-jun promoter involves the MEF2 transcription factor. Evidence for a novel c-jun amino-terminal kinase-independent pathway.
P50
Q24317541-7555C685-225A-471E-B4E3-8C221D933DCDQ24646815-54D5DFC8-C8B1-4E11-9526-AF8F64865F1AQ28297176-51C373D2-8B31-4B01-8939-FBC2948EFDC0Q30874197-5845AA4E-F4F5-4222-AF4D-642787D6B0B4Q33959529-F61E67F8-A83B-4791-8B2F-06C000953432Q34008829-D8796361-7760-49D5-BA3E-E5EA0224C43CQ34012467-08459522-38AC-4F04-B5BA-6E2E363EA81BQ34356435-C9728681-4E32-421F-B52E-2A57D0B84B34Q34769536-729F644B-F2E0-46FE-922B-F084208BA562Q35100724-529A8EF4-E99F-409B-98FB-E738FD48F00AQ35243831-E366A871-B809-47F4-8EA9-8F8ED291971DQ35687931-0ADFA615-F5A8-40B4-8F85-3EF3D84AA098Q35781371-EC7F0492-7FB5-4E61-AACB-1B47F43314C9Q35978729-BAC00E33-B719-4741-BCD3-931BFFB474F2Q36126283-EFA8E3A2-F23F-4E65-A603-9699B9052A7BQ36357411-72AC4CE9-86A7-46A5-A2BC-87071FAC3924Q37022229-5A5CEF74-5185-47E7-BB40-AEBC63B45A21Q37022229-CD725086-651F-4813-8B0F-7D02385D1EB6Q37890422-7CA812E3-8D6D-4DC8-8224-332BE0AE80C7Q37992502-53D456BF-472C-49C7-8593-2E09DF7FCDCAQ37992502-9421578C-F73E-4DDC-A90B-12637C99D486Q38803515-A7E265F8-EE39-4CA0-849E-81716DF807FAQ38930799-B2E0DE98-136A-4C74-91C6-C86FF43D73F7Q39362227-195F6C5B-3C9F-466B-A348-756A97F7BE3FQ39618338-E3C13734-6CD5-4031-89A2-2EC5F55D3FB4Q39697053-52DF4AA1-6214-4237-95C9-A54A963B94EDQ39791161-31CD1ADA-F1E4-4634-B8B3-E0157A23F005Q39905840-32A30FD2-7957-4573-B57E-E6B47A7E340DQ40009485-25D7BA6E-0CEF-4DA6-A26C-0EA5EC2DECE6Q40174892-3D60454C-059B-4630-A4FE-883CB68CC929Q40430082-44E32E5B-8BA7-4F5E-B62F-EBFA39BE8A06Q40504798-E7B70BCF-1191-49F8-B6E5-064D77E4C501Q40513977-D5DCCF1A-FD75-43DB-8D32-EF8937060188Q40582876-F1472DDA-853B-4A46-9481-F69E74CC80C3Q40669748-0977822D-4548-44E8-BDB9-5CA514F4DA47Q40735119-A03FF26F-017C-4AF2-874F-F568A405EE6FQ40810899-76F219CF-6B60-4CAF-95E5-A4D616966448Q40890957-3E8FEB04-3289-4ADE-8465-9C8704733F51Q41191107-847576EC-DC3A-47F5-BEB7-5EE2A008CAD7Q41882652-633D8F8F-0B31-4EA1-B1E2-9D61E90CA3B6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Juan C. Lacal
@en
Juan C. Lacal
@nl
Juan C. Lacal
@sl
Juan Carlos Lacal Sanjuan
@es
type
label
Juan C. Lacal
@en
Juan C. Lacal
@nl
Juan C. Lacal
@sl
Juan Carlos Lacal Sanjuan
@es
altLabel
Juan C. Lacal
@es
Juan Carlos Lacal Sanjuan
@en
prefLabel
Juan C. Lacal
@en
Juan C. Lacal
@nl
Juan C. Lacal
@sl
Juan Carlos Lacal Sanjuan
@es
P108
P1053
N-9064-2015
P106
P1153
7004811766
P1950
P21
P31
P3829
P496
0000-0002-1908-2777